Dr. Rebecca Manno of the Johns Hopkins Arthritis Center discusses exercise, joint damage and flares in arthritis patients.
Will Exercise Cause Damage to My Joints or Cause a Flare?
Rheumatoid Arthritis News
Dental Health and Rheumatoid Arthritis: A Research Update
Key Points The Johns Hopkins Arthritis Center conducted a study to determine the presence of gum disease in patients who have Rheumatoid Arthritis (RA). Oral health exams were performed on […]
Arthritis Center Researchers Find that Yoga Improves Arthritis Symptoms and Mood
A recent study by the Johns Hopkins Arthritis Center reveals yoga holds positive results for arthritis sufferers in terms of both mind and body.
OTREXUP™ (methotrexate) injection approved by the FDA
OTREXUP™ (methotrexate) injection was recently approved by the U.S. Food and Drug Administration.
It is indicated for adults with severe, active rheumatoid arthritis, or children with active polyarticular juvenile idiopathic arthritis who have failed first line therapies. It is also indicated for severe, recalcitrant, disabling psoriasis.
Tofacitinib: A novel Janus kinase inhibitor is FDA approved as the first oral biologic treatment for rheumatoid arthritis
Tofacitinib (Xeljanz®) is the first of a unique class of oral kinase inhibitors to be FDA approved for the treatment of rheumatoid arthritis (RA). Tofacitinib is a selective inhibitor of Janus kinase (JAK) enzymes.
Challenges in Screening for Latent TB in Inflammatory Arthritis
Screening for latent TB in patients with inflammatory arthritis who will be starting TNFα inhibitors is important to prevent complications of TB-reactivation. However, currently there is no ‘gold standard’ for the diagnosis of latent TB.
